BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/24/2026 6:27:54 AM | Browse: 21 | Download: 69
 |
Received |
|
2025-12-26 01:45 |
|
Peer-Review Started |
|
2025-12-26 01:45 |
|
First Decision by Editorial Office Director |
|
2026-01-06 08:49 |
|
Return for Revision |
|
2026-01-06 08:49 |
|
Revised |
|
2026-01-23 09:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-02 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-02 10:31 |
|
Articles in Press |
|
2026-03-02 10:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-17 02:52 |
|
Publish the Manuscript Online |
|
2026-03-24 06:27 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Retrospective Study |
| Article Title |
Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ammar Chapra, Fateen Ata, Amal Abdellatif, Mohammed Nofal, Ahmed Daniyal, Asma Mohammad Younus, Jassim Zaheen Shah and Kakil Rasul |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fateen Ata, Academic Fellow, MD, Principal Investigator, Department of Internal Medicine, Cleveland Clinic Foundation, 9500, Cleveland Clinic, Cleveland, OH 44118, United States. docfateenata@gmail.com |
| Key Words |
Immune checkpoint inhibitors; Cardiotoxicity; Myocarditis; Pericarditis; Cardiomyopathy; Heart failure; Middle East; Qatar; Pembrolizumab |
| Core Tip |
Immune checkpoint inhibitors (ICIs) have revolutionized treatments and outcomes in oncology, but can cause serious ICI-related cardiac adverse events. This first comprehensive Middle Eastern study revealed that delayed-onset heart failure, rather than myocarditis, predominated among affected patients, with pembrolizumab being the most common implicated ICI. The 2.1% incidence and high mortality necessiates the need for early cardiac surveillance and risk stratification. |
| Publish Date |
2026-03-24 06:27 |
| Citation |
Chapra A, Ata F, Abdellatif A, Nofal M, Daniyal A, Mohammad Younus A, Shah JZ, Rasul K. Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East. World J Clin Cases 2026; 14(9): 118187 |
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i9/118187.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i9.118187 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
